法布瑞氏症 - 機會分析及至2024年的預測
OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024
|出版日期||內容資訊||英文 133 Pages
|法布瑞氏症 - 機會分析及至2024年的預測 OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024|
|出版日期: 2015年08月01日||內容資訊: 英文 133 Pages||
GlobalData estimates the 2014 sales for the Fabry disease market at approximately $682m across the 7MM. The US contributed the majority of these sales, generating an estimated $295m. By the end of the forecast period in 2024, Fabry disease sales are expected to grow to $1.25 billion at a Compound Annual Growth Rate (CAGR) of 6.3% over the 10-year period. The majority of sales in the 7MM in 2024 will come from the US, which will represent 44.2% of the market. GlobalData expects an increase in the number of newly diagnosed cases of Fabry disease, and consequently in the number of treatable Fabry patients, as a result of increasing awareness of Fabry disease among physicians. ERT is now well established in the treatment of Fabry disease; however, there still remains concern about its efficacy, tissue penetrance, and intravenous administration. As a result, alternative approaches are being investigated to advance new treatments for Fabry disease, which focus on three main areas of research: chaperone therapies, substrate reduction therapies (SRTs), and combinations of their use with ERT.